18:35 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Syros' SY-1425 plus Vidaza leads to 63% ORR in biomarker-positive AML cohort

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) reported Phase II data from a cohort of eight evaluable newly diagnosed, biomarker-positive acute myelogenous leukemia (AML) patients showing that tamibarotene (SY-1425) plus Vidaza azacitidine from Celgene Corp. (NASDAQ:CELG) led to...
19:35 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

FDA approves Teva's Trisenox for newly diagnosed APL

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said FDA approved Trisenox arsenic trioxide plus tretinoin to treat adults with newly diagnosed low-risk acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or...
02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
16:22 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Syros discontinues single agent tamibarotene

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) said only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy achieved a complete response in a Phase II trial to treat relapsed or refractory acute myelogenous leukemia (AML) and...
23:07 , Dec 11, 2017 |  BC Extra  |  Clinical News

Syros falls on Phase II AML, MDS data

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) lost $3.92 (32%) to $8.45 on Monday after reporting that only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy achieved a complete response in a Phase II trial to...
21:27 , Oct 26, 2017 |  BC Innovations  |  Tools & Techniques

Ripe for enhancement

Although still largely the purview of academics, technologies for mapping enhancers to the genes they control are rapidly gaining efficiency and promise to unlock a trove of new targets for drug developers. But companies will...
00:32 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

FDA grants Priority Review to Teva's Trisenox sNDA

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said FDA accepted and granted Priority Review to an sNDA for Trisenox arsenic trioxide plus all-trans retinoic acid (ATRA) for induction of remission and consolidation in patients with...
22:44 , Apr 21, 2017 |  BC Extra  |  Financial News

Syros, SteadyMed complete private placements

Cancer company Syros Pharmaceuticals Inc. (NASDAQ:SYRS) and drug delivery play SteadyMed Ltd. (NASDAQ:STDY) raised a total of $65 million in private placements on Friday. Syros raised $35 million through the sale of 2.6 million shares...
14:22 , Apr 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest promoting MSR-1 expression could help treat ischemic stroke. MSR-1 levels were higher in brain-derived myeloid cells from a mouse model of ischemic stroke than cells from normal mice. In the...
00:40 , Nov 22, 2016 |  BC Week In Review  |  Clinical News

Trisenox regulatory update

The European Commission approved a label expansion for Trisenox arsenic trioxide from Teva to include treatment of acute promyelocytic leukemia (APL) in combination with retinoic acid. The product is approved in the EU for induction...